Q32 Bio

QTTBPhase 2

Cambridge, United StatesFounded 2019q32bio.com

Q32 Bio is focused on discovering and developing innovative therapies that restore immune homeostasis in severe autoimmune and inflammatory diseases. The company's most advanced program, bempikibart, has shown promising clinical activity and a favorable safety profile in a Phase 2a trial for alopecia areata. Led by an experienced team of industry veterans, Q32 Bio is advancing a pipeline centered on modulating both the adaptive (via IL-7/TSLP) and innate (via complement) immune systems, with strategic evaluation ongoing for its complement platform.

Market Cap

$826.9M

Founded

2019

Focus

AntibodiesBiologics

QTTB · Stock Price

USD 56.52279.36 (-83.17%)

Historical price data

AI Company Overview

Technology Platform

Q32 Bio's core technology involves modulating the adaptive immune system via IL-7/TSLP pathway blockade and developing tissue-targeted complement inhibitors through a novel discovery platform for C3d fusion proteins and nanobodies.

Pipeline Snapshot

4 drugs in pipeline

Drug	Indication	Stage
ADX-097	IgA Nephropathy	Phase 2
ADX-914 + Placebo	Atopic Dermatitis	Phase 2
bempikibart (ADX-914)	Alopecia Areata	Phase 2
ADX-914 + Placebo + ADX-914 + Placebo	Safety Issues	Phase 1

Funding History

Total raised: $216M

IPO$110MUndisclosedNov 9, 2023

Series B$60MOrbiMedApr 15, 2022

Series A$46MAbingworthOct 15, 2020

Opportunities

The primary growth opportunity is the successful development and approval of bempikibart for alopecia areata, a disease with high unmet need and a validated market.

Further opportunities exist in expanding bempikibart into other T-cell mediated autoimmune diseases.

The tissue-targeted complement platform represents a disruptive long-term opportunity to treat a broad range of complement-mediated disorders with potentially superior safety.

Risk Factors

Key risks include clinical trial failure of the lead asset, insufficient funding to reach key milestones, intense competition in both the alopecia and complement therapeutic spaces, and execution risks associated with strategic decisions for the complement platform.

Competitive Landscape

In alopecia areata, main competitors are approved JAK inhibitors (Eli Lilly's Olumiant, Pfizer's Litfulo). Q32 Bio differentiates via its novel IL-7/TSLP mechanism targeting adaptive immunity. In complement, it faces large players like AstraZeneca and Apellis, with differentiation hinging on its tissue-targeted approach designed to improve safety over systemic inhibitors.